0001171843-22-000175.txt : 20220110 0001171843-22-000175.hdr.sgml : 20220110 20220110080214 ACCESSION NUMBER: 0001171843-22-000175 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220110 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 22519755 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_011022.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2022-01-10 2022-01-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 10, 2022

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

181 Oyster Point Blvd.

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 

In this report, "GBT," "Company," "we," "our," and "us" means Global Blood Therapeutics, Inc., and/or one or more of our subsidiaries, unless the context otherwise provides.

Item 8.01. Other Events.

On January 10, 2022, Global Blood Therapeutics, Inc. issued a press release titled "Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
   
99.1 Press Release dated January 10, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: January 10, 2022By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Drug Administration (FDA), is now available through GBT’s specialty pharmacy partner network in the United States.

On December 17, 2021, the FDA approved Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in children ages 4 to less than 12 years – expanding the previously approved use of Oxbryta to treat SCD in patients ages 12 years and older in the U.S. The FDA also approved Oxbryta tablets for oral suspension, the new dispersible tablet dosage form suitable for patients ages 4 to less than 12 years. Oxbryta is the first and only approved medicine that directly targets sickle hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD.

“The sickle cell disease community needs more innovative, safe and effective treatment options for this disease – a fact central to GBT’s mission,” said Kim Smith-Whitley, M.D., executive vice president and head of research and development at GBT. “The FDA’s recent approval of the new dispersible tablet dosage form of Oxbryta is an important advance for people and families affected by this devastating disease, and we are pleased to make this new dosage form available to patients by prescription. We are grateful to all those involved in ensuring that more sickle cell disease patients who need treatment with Oxbryta have access to it.”

Oxbryta is now available by prescription in two dosage forms for patients 4 years and older based on the patient’s age, weight, and ability to swallow tablets: 500 mg tablets and 300 mg tablets for oral suspension. The 300 mg dispersible tablets for oral suspension are available in bottles of 60 and 90 tablets. The dispersible tablets include grape flavoring and are intended to be dispersed in room-temperature clear drinks for ease of swallowing (such as drinking water or clear soda), making Oxbryta easier to take for patients who have difficulty swallowing whole tablets, particularly younger children.

GBT is committed to ensuring that patients who are prescribed Oxbryta can access their medicine. GBT Source Solutions® was established by GBT as a comprehensive program for patients who are prescribed Oxbryta that provides a wide range of practical, educational and financial support customized to each patient’s needs. GBT Source Solutions provides support by reviewing insurance coverage options and explaining benefits; explaining specialty pharmacy benefits and working with the specialty pharmacies that coordinate shipments of Oxbryta; helping eligible, commercially insured patients with co-pay assistance; and helping appropriate patients stay on treatment with a nurse support team. More information is available at Oxbryta.com or 1-833-428-4968 (1-833-GBT-4YOU).

About Sickle Cell Disease
Sickle cell disease (SCD) affects more than 100,000 people in the United States,1 an estimated 52,000 people in Europe,2 and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa.3 It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.3 SCD is a lifelong inherited rare blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.4 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.4-6 The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.5-8 Complications of SCD begin in early childhood and can include neurocognitive impairment, acute chest syndrome, and silent and overt stroke, among other serious issues.9

About Oxbryta® (voxelotor) Tablets and Tablets for Oral Suspension
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, Oxbryta inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells leading to hemolysis and hemolytic anemia, which are primary pathologies faced by every single person living with SCD. Through addressing hemolytic anemia and improving oxygen delivery throughout the body, GBT believes that Oxbryta has the potential to modify the course of SCD. In November 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Oxbryta tablets for the treatment of SCD in adults and children 12 years of age and older, and in December 2021, the U.S. FDA expanded the approved use of Oxbryta for the treatment of SCD in patients 4 years of age and older.10

As a condition of accelerated approval for patients ages 4 and older in the United States, GBT will continue to study Oxbryta in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of the therapy to decrease stroke risk in children 2 to 14 years of age.

In recognition of the critical need for new SCD treatments, the FDA granted Oxbryta Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations for the treatment of patients with SCD. Additionally, Oxbryta has been granted Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), Oxbryta was designated by the European Commission (EC) as an orphan medicinal product for the treatment of patients with SCD, and Oxbryta was granted Promising Innovative Medicine (PIM) designation in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA).

In December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion recommending marketing authorization for Oxbryta in Europe for the treatment of hemolytic anemia due to SCD in adults and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea). The Ministry of Health and Prevention (MOHAP) in the United Arab Emirates (UAE) has granted marketing authorization for Oxbryta for the treatment of SCD in adults and children 12 years of age and older.

Important Safety Information
Oxbryta should not be taken if the patient has had an allergic reaction to voxelotor or any of the ingredients in Oxbryta. See the end of the patient leaflet for a list of the ingredients in Oxbryta. Oxbryta can cause serious side effects, including serious allergic reactions. Patients should tell their healthcare provider or get emergency medical help right away if they get rash, hives, shortness of breath (difficult breathing) or swelling of the face.

The most common side effects of Oxbryta include headache, diarrhea, stomach-area (abdominal) pain, nausea, rash or hives, and fever. The most common side effects of Oxbryta in children ages 4 to less than 12 years of age include fever, vomiting, rash, stomach-area (abdominal) pain, diarrhea, and headache. These are not all the possible side effects of Oxbryta. Before taking Oxbryta, patients should tell their healthcare provider about all medical conditions, including if they have liver problems; if they are pregnant or plan to become pregnant as it is not known if Oxbryta can harm an unborn baby; or if they are breastfeeding or plan to breastfeed as it is not known if Oxbryta can pass into breastmilk or if it can harm a baby. Patients should not breastfeed during treatment with Oxbryta and for at least 2 weeks after the last dose.

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines may affect how Oxbryta works. Oxbryta may also affect how other medicines work and may affect the results of certain blood tests.

Patients are advised to call their doctor for medical advice about side effects. Side effects can be reported to FDA at 1-800-FDA-1088. Side effects can also be reported to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).

Full Prescribing Information for Oxbryta is available at Oxbryta.com.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets and tablets for oral suspension, the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, dedication, commitment, focus, goals, mission and vision; safety, efficacy and mechanism of action of Oxbryta and other product characteristics; significance of reducing sickling and hemolysis and raising hemoglobin; commercialization, delivery, availability, use and commercial and medical potential of Oxbryta; ongoing and planned studies, clinical trials and registries, and related protocols, activities, timing and other expectations; significance of the FDA’s approval of GBT’s regulatory submissions to expand the approved use of Oxbryta for more patients and in a pediatric formulation in the U.S., including in advancing the treatment of SCD, the suitability, use and potential of such pediatric formulation and the impact on patients and others; GBT’s commitment to ensuring access to Oxbryta, including the availability, use and impact of GBT Source Solutions; expanding the approved use of Oxbryta to treat patients in Europe and other territories, including potential regulatory review, timing and approval; altering the treatment, course and care of SCD and mitigating related complications; safety, efficacy, mechanism of action, advancement and potential of GBT’s drug candidates and pipeline; and working on new targets and discovering, developing and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control, including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease; the risks that GBT is continuing to establish its commercialization capabilities and may not be able to successfully commercialize Oxbryta; risks associated with GBT’s dependence on third parties for research, development, manufacture, distribution and commercialization activities; government and third-party payer actions, including those relating to reimbursement and pricing; risks and uncertainties relating to competitive treatments and other changes that may limit demand for Oxbryta; the risks regulatory authorities may require additional studies or data to support continued commercialization of Oxbryta; the risks that drug-related adverse events may be observed during commercialization or clinical development; data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval; compliance with obligations under the Pharmakon loan; and the timing and progress of activities under GBT’s collaboration, license and distribution agreements; along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

References

  1. Centers for Disease Control and Prevention website. Sickle Cell Disease Research. https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-understanding-sickle-cell-disease.html. Accessed December 1, 2021.
  2. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125. Accessed June 12, 2020.
  3. Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 3, 2019.
  4. National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed August 5, 2019.
  5. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
  6. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
  7. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760. 
  8. Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
  9. Kanter J, et al. Blood Rev. 2013 Nov;27(6):279-87.
  10. Oxbryta (voxelotor) tablets and tablets for oral suspension prescribing information. South San Francisco, Calif. Global Blood Therapeutics, Inc.; December 2021.

Contact Information:
Steven Immergut (media)
+1 650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
+1 650-351-7881
croberts@gbt.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 10, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 10, 2022
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 181 Oyster Point Blvd.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_011022_htm.xml IDEA: XBRL DOCUMENT 0001629137 2022-01-10 2022-01-10 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2022-01-10 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 181 Oyster Point Blvd. South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_011022.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_011022.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_011022.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_011022.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_011022.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-000175-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-000175-xbrl.zip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end